ABBV vs ALMS
ABBV: Global biopharmaceutical company with leadership positions in immunology, neuroscience, oncology, and aesthetics targeting complex diseases. ALMS: A clinical-stage biopharmaceutical company developing TYK2 inhibitors to replace broad immunosuppression with targeted therapies for immune-mediated diseases, with lead candidate envu advancing toward 2026 FDA submission.
Side-by-side fundamentals
| Metric | ABBV | ALMS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $253.30 | $28.81 | |
| Market cap as of 2026-07-23 | $452.5B | $3.8B | |
| P/E as of 2026-07-23 | 124.48 | n/a | |
| PEG as of 2026-07-23 | 5.72 | n/a | |
| Net margin as of 2026-07-23 | +5.8% | -1013.2% | ABBV higher |
| Gross margin as of 2026-07-23 | +72.0% | n/a | |
| Operating margin as of 2026-07-23 | +24.4% | -1109.1% | ABBV higher |
| ROE as of 2026-07-23 | +95.6% | -54.7% | ABBV higher |
| ROA as of 2026-07-23 | +2.7% | -43.6% | ABBV higher |
| Debt / equity as of 2026-07-23 | 49.22 | 0.00 | ALMS lower |
| Revenue growth (YoY) as of 2026-07-23 | +9.5% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +1.8% | n/a | |
| Dividend yield as of 2026-07-23 | +2.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.27 | 0.82 | |
| 1-year return as of 2026-07-22 close | +35.4% | +805.1% | ALMS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.